$MTNB
Matinas BioPharma Holdings Inc Stock $mtnb

$mtnb Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414048056 Filed on August 08, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$1.070M	$1.118M	$240.1K
YoY Change	43.59%	365.72%
% of Gross Profit
Depreciation & Amortization	$30.00K	$10.00K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$2.605M	$2.420M	$343.4K
YoY Change	79.3%	604.92%
Operating Profit	-$2.605M	-$2.420M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$6.495K	-$5.385K
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$2.612M	-$2.426M	-$343.3K
YoY Change	79.34%	606.6%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	32.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.010M	$6.650M	$420.0K
YoY Change	-60.14%	1483.33%
Cash & Equivalents	$5.007M	$6.647M	$461.5K
Short-Term Investments
Other Short-Term Assets	$110.0K	$40.00K
YoY Change	266.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.110M	$6.686M	$420.0K
YoY Change	-59.44%	1491.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$360.0K	$361.6K
YoY Change	1100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$320.0K	$320.0K
YoY Change
Total Long-Term Assets	$680.0K	$677.8K	$0.00
YoY Change	2166.67%
TOTAL ASSETS
Total Short-Term Assets	$5.110M	$6.686M	$420.0K
Total Long-Term Assets	$680.0K	$677.8K	$0.00
Total Assets	$5.790M	$7.363M	$420.0K
YoY Change	-54.16%	1653.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$210.0K	$281.1K	$60.00K
YoY Change	-19.23%	368.48%
Accrued Expenses	$764.7K	$547.3K
YoY Change	218.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$20.00K
YoY Change		-100.0%
Long-Term Debt Due	$40.00K	$40.00K
YoY Change
Total Short-Term Liabilities	$1.021M	$870.0K	$80.00K
YoY Change	104.13%	987.5%
LONG-TERM LIABILITIES
Long-Term Debt	$20.00K	$30.00K	$460.0K
YoY Change		-93.48%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$20.00K	$30.00K	$460.0K
YoY Change		-93.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.021M	$870.0K	$80.00K
Total Long-Term Liabilities	$20.00K	$30.00K	$460.0K
Total Liabilities	$1.043M	$910.0K	$540.0K
YoY Change	108.62%	68.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.01M	-$8.396M
YoY Change
Common Stock	$3.217K	$3.200K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.746M	$6.457M	-$120.0K
YoY Change
Total Liabilities & Shareholders Equity	$5.789M	$7.363M	$420.0K
YoY Change	-54.17%	1653.17%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$2.612M	-$2.426M	-$343.3K
YoY Change	79.34%	606.6%
Depreciation, Depletion And Amortization	$30.00K	$10.00K	$0.00
YoY Change
Cash From Operating Activities	-$1.610M	-$1.850M	-$280.0K
YoY Change	80.9%	560.71%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$70.00K
YoY Change	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$30.00K	-$70.00K
YoY Change	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	80.00K
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.610M	-1.850M	-280.0K
Cash From Investing Activities	-30.00K	-70.00K
Cash From Financing Activities	0.000	0.000	80.00K
Net Change In Cash	-1.640M	-1.920M	-200.0K
YoY Change	-113.54%	860.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.610M	-$1.850M	-$280.0K
Capital Expenditures	-$30.00K	-$70.00K
Free Cash Flow	-$1.580M	-$1.780M
YoY Change	83.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	361645	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	6685544	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: bold 10pt Times New Roman, Times, Serif"> </div> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>[2]</div> </td> <td> <div>Use of Estimates</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: bold 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6647479	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10840428	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38065	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: bold 10pt Times New Roman, Times, Serif"> </div> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>[4]</div> </td> <td> <div>Concentration of Credit Risk</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Cash balances are maintained principally at one major U.S. financial institution and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. At various times throughout the period ended June 30, 2014, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	84493	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	10924921	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	547326	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	3200	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	3200	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	93057	USD
CY2014Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	316105	USD
CY2013Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	315778	USD
CY2014Q2	us-gaap	Assets Assets	7363294	USD
CY2013Q4	us-gaap	Assets Assets	11333756	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	281090	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	396768	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14849896	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14302307	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8395613	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3830719	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	6457483	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	10474788	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7363294	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11333756	USD
	mtnb	Stock To Be Issued Upon Exercise StockToBeIssuedUponExercise	0	shares
	mtnb	Stock To Be Issued Upon Exercise StockToBeIssuedUponExercise	18309082	shares
CY2013Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2400000	USD
CY2013Q3	mtnb	Placement Agent Cash Fees And Expenses PlacementAgentCashFeesAndExpenses	1950000	USD
CY2013Q3	mtnb	External Legal Costs ExternalLegalCosts	425000	USD
CY2013Q3	mtnb	Placement Agent Fees Per Month PlacementAgentFeesPerMonth	20000	USD
CY2013Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	34000	USD
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15250000	shares
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32000000	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7140	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0187	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M14D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.94
CY2014Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5190918	shares
CY2013Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8250000	shares
CY2014Q2	mtnb	Employee Service Share Based Compensation Total Compensation Cost Not Yet Recognized Stock Options Grants EmployeeServiceShareBasedCompensationTotalCompensationCostNotYetRecognizedStockOptionsGrants	1350000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y3M18D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3059802	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.94
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	808764	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.94
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	88770	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	154140	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	157076	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	160014	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	582797	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1142797	USD
	mtnb	Increase Decrease In Lease Rental Expense IncreaseDecreaseInLeaseRentalExpense	14200	USD
CY2014Q2	us-gaap	Security Deposit SecurityDeposit	300000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2357483	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	103257	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1302236	USD
	us-gaap	Operating Expenses OperatingExpenses	455504	USD
	us-gaap	Operating Expenses OperatingExpenses	4549514	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	343371	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	2420487	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-455504	USD
CY2013Q4	us-gaap	Lessor Leasing Arrangements Operating Leases Term Of Contract LessorLeasingArrangementsOperatingLeasesTermOfContract	P7Y
CY2014Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2072	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	12723	USD
	mtnb	Security Deposits Reduced By Straight Line Basis Description SecurityDepositsReducedByStraightLineBasisDescription	June 1, 2015, this deposit can be reduced by $100,000 on an annual basis, down to $50,000, as long as the Company makes timely rental payments.
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	289700	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2192031	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	240114	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1118251	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	165804	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4549514	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-343371	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2420487	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	57	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-15381	USD
CY2013Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	57	USD
CY2014Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5385	USD
	us-gaap	Net Income Loss NetIncomeLoss	-455447	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4564895	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-343314	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2425872	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10000000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32000000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10000000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32000000	shares
	us-gaap	Depreciation Depreciation	3577	USD
	us-gaap	Depreciation Depreciation	19931	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	547589	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4471	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	49024	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-19827	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	43368	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	162520	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	22911	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-115678	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-434615	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3935177	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	257772	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-257772	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	24100	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	500001	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	mtnb	Payments Of Preferred Stock Issuance Costs PaymentsOfPreferredStockIssuanceCosts	4140	USD
	mtnb	Payments Of Preferred Stock Issuance Costs PaymentsOfPreferredStockIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	471761	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	37146	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-4192949	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	424364	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	461510	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Matinas BioPharma Holdings, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001582554
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Trading Symbol TradingSymbol	MTNB
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32000000	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q3	mtnb	Securities Penalty Payment Description SecuritiesPenaltyPaymentDescription	Holdings shall pay to each holder of registrable securities purchased in 2013 Private Placement an amount in cash equal to half of one percent (0.5%) of such holders investment amount on every thirty (30) day anniversary of such failure to maintain the registration statement until such failure was cured
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04	pure
CY2014Q2	mtnb	Sharebased Compensation Arrangement By Sharebased Payment Award Increase Of Shares Offering Date SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate	January 1, 2015
	mtnb	Warrant Callable Price WarrantCallablePrice	at any time the common stock trades above $5.00 for twenty (20) consecutive days following the effectiveness of the registration statement
CY2013Q3	mtnb	Effectiveness Of Registration Statement Description EffectivenessOfRegistrationStatementDescription	If this registration statement was not declared effective on or before the Effectiveness Deadline, Holdings would have been required to pay to each holder of registrable securities purchased in the 2013 Private Placement an amount in cash equal to one half of one percent (0.5%) of such holders investment amount on every thirty (30) day anniversary of such Effectiveness Deadline until such failure was cured.

Files In Submission

Name	View Source	Status
0001144204-14-048056-index-headers.html	Edgar Link	pending
0001144204-14-048056-index.html	Edgar Link	pending
0001144204-14-048056.txt	Edgar Link	pending
0001144204-14-048056-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mtnb-20140630.xml	Edgar Link	completed
mtnb-20140630.xsd	Edgar Link	pending
mtnb-20140630_cal.xml	Edgar Link	unprocessable
mtnb-20140630_def.xml	Edgar Link	unprocessable
mtnb-20140630_lab.xml	Edgar Link	unprocessable
mtnb-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v385154_10q.htm	Edgar Link	pending
v385154_ex31-1.htm	Edgar Link	pending
v385154_ex31-2.htm	Edgar Link	pending
v385154_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTNB
Matinas BioPharma Holdings Inc Stock $mtnb

2014 Q3 Form 10-Q Financial Statement

#000114420414048056 Filed on August 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB Matinas BioPharma Holdings Inc Stock $mtnb

2014 Q3 Form 10-Q Financial Statement

#000114420414048056 Filed on August 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB
Matinas BioPharma Holdings Inc Stock $mtnb